A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 900 articles on Celgene.
Is Celgene Corporation a Buy?

Risks? Celgene has plenty of them. But the big biotech also looks like a bargain with tremendous ...

3 Great Stocks for Your IRA

Looking for stocks to boost your retirement savings? Here are three winners that should appeal to...



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $87.72
Prev Close: $88.30
Open: $88.62
Bid: $87.51
Ask: $87.70
Day's Range: $87.45 - $89.17
52wk Range: $74.13 - $147.17
Volume: 6,618,412
Avg Vol 4,204,004
Market Cap: $69B
P/E (ttm): 20.49
EPS (ttm): $4.31
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2308 Outperform
78 Underperform
CAPS All Stars
 
478 Outperform
13 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

80% Approve

Based on 75 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers